The MONARCH trial suggested a significantly higher incidence of [[neutropenia]] in patients receiving 200 mg sarilumab every 2 weeks, compared to patients being treated with [[adalimumab]] (13.6% vs 0.5%). However, infection rates were similar between both groups (28.8% vs 27.7%).<ref name=MPT-monarch/>

 

